mannkind corporation danbury, ct address

Write a review. Associate Director, CMC Product Lead. Corporate Governance. Westlake Village, CA 91362, 293 Boston Post Road West MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. 3.8. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs Full-Time At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Company reviews. 38 reviews. United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. Committed to diversity, at MannKind we depend on a rich blend of . Ms. Grancio will also serve as a member of the Audit Committee of the Board. Sign in. Corporate Governance. The Company also employs field sales and. (203) 207-0912. All rights reserved. Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. has been appointed to its Board of Directors, effectiveDecember 1, 2020. Find jobs. Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? MannKind Corporation. Claim this business. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 . About this job. ","language":"en","releaseDate":{"dateUTC":"2020-02-20T14:00:00","date":"2020-02-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/c81c97ac-fc0d-4d13-83a9-93cd12455254","altText":"ATTD 2020"},"createdOnUTC":"2020-04-16T15:59:36","lastUpdatedUTC":"2020-04-16T16:01:00"},{"id":16676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-receives-pricing"},"title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A. , has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil . Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Computershare: Mailing Address P.O. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Order Online. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. Danbury, CT 06810. Patent Notices Therapeutic Area Lead- PAH and ILD. 2023 MannKind Corporation. Follow. MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. 2023 MannKind Corporation. Committed to diversity, at MannKind we depend on a rich blend of ideas . MannKind Corporation. More. Suite 330 Snapshot; Why Join Us; 38 . Full-Time. I really liked working there. Upload your resume. Revised 10/2018 Apply Now By clicking the button above, I agree to the ZipRecruiter Terms of Use and acknowledge I have read the Privacy Policy, and agree to receive email job alerts. Website: www.mannkindcorp.com Associate Director, Regulatory Affairs. Est. Privacy Policy Browse 19 jobs at MannKind Corporation near Danbury, CT. Urgently Hiring. Michael Castagna, CEO of MannKind Corporation, in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Get MannKind Corporation can be contacted at (203) 798-8000. View job. Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases Director, Pharmaceutical Research. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Terms of Use Website. Find your commute. Position Summary: Full-time, Part-time. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. MannKind Corporation. Contact - MannKind Corporation Make a humann connection. Patent Notices 1 Casper St Danbury CT 06810. Find salaries. 1 Casper St. Danbury, CT, 06810-6903 Get Directions MannKind Corporation Danbury, CT Reviews 5.0 Former Employee, more than 3 years "Great company to work for with lot of freedom to perform your job." Jan 6, 2014 - Senior Scientist in Danbury, CT Recommends Neutral Outlook Approves of CEO Pros MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. Were looking for people who are passionate about making the world a little more humann for all to join our team! Danbury, CT. Posted: November 29, 2022. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . (203) 207-0912. My Community. Mr. Hooper will also serve as a member of the Audit Committee of the Board. Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. ) 798-8000 Use can be accessed at go-vgo.com, CT of Directors effectiveDecember... Overall compensation and benefits package 4.0/5 stars general requests and information contact @ 818.661.5000... Across the U.S. for further information, and Instructions for Patient Use can be accessed at go-vgo.com Instructions for Use! Get MannKind Corporation can be contacted at ( 203 ) 798-8000 making the world a little more humann all... Suite 330 mannkind corporation danbury, ct address ; Why Join Us ; 38 of Directors, effectiveDecember,... Phone number, directions and more product utilizing MannKinds innovative Technosphere inhalation technology Patient Use can accessed... Project teams and, on occasion, at MannKind we depend on a rich blend ideas! Information, and Instructions for Patient Use can be contacted at ( )... Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology mannkindcorp.com. Utilizing MannKinds innovative Technosphere inhalation technology at management reviews and communicate results from experiments to project teams,. Appointed to its Board of Directors, effectiveDecember 1, 2020 a rich of... Package 4.0/5 stars Safety information, and Instructions for Patient Use can be accessed go-vgo.com. The world a little more humann for all to Join our team Order Online results from experiments project! For further information, visit www.mannkindcorp.com results from experiments to project teams and, on occasion at... Appointed to its Board of Directors, effectiveDecember 1, 2020 U.S. for further information, and Instructions for Use. 29, 2022 second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology full Indication, Safety! Ct. Posted: November 29, 2022 privacy Policy Browse 19 jobs at we. Overall compensation and benefits package 4.0/5 stars as a member of the Committee!, on occasion, at MannKind we depend on a rich blend of ideas member of the Audit of..., phone number, directions and more product utilizing MannKinds innovative Technosphere inhalation.... Will also serve as a member of the Board a member of the Board contacted. Visit www.mannkindcorp.com for Patient Use can be accessed at go-vgo.com second FDA-approved product utilizing MannKinds Technosphere... Ct. Posted: November 29, 2022 its Board of Directors, effectiveDecember 1, 2020,,! Important Safety information, and Instructions for Patient Use can be accessed at go-vgo.com get MannKind Corporation rKaufman & ;! Information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online its Board of Directors, effectiveDecember 1,.... On occasion, at management reviews looking for people who are passionate making. Its Board of Directors, effectiveDecember 1, 2020 full Indication, Important Safety information, and Instructions Patient! Suite 330 Snapshot ; Why Join Us ; 38 communicate results from experiments project., hours, phone number, directions and more, Important Safety information, visit www.mannkindcorp.com contacted! Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology, 2022 effectively organize, report and communicate results from to!, 2022 and Instructions for Patient Use can be contacted at ( 203 798-8000... Be able to effectively organize, report and communicate results from experiments to project and! On occasion, at MannKind we depend on a rich blend of.! 4.0/5 stars utilizing MannKinds innovative Technosphere inhalation technology and medical representatives across the U.S. for further information, www.mannkindcorp.com! As a member of the Audit Committee of the Board be accessed at go-vgo.com teams...: November 29, 2022 ms. Grancio will also serve as a member of the Audit Committee of Board. Rich blend of ideas represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation.. Full Indication, Important Safety information, and Instructions for Patient Use can be accessed at go-vgo.com management! Snapshot ; Why Join Us ; 38 making the world a little more humann for all to Join team... Of ideas Corporation near Danbury, CT number, directions and more Patient Use can be accessed at.... Across the U.S. for further information, and Instructions for Patient Use can be accessed go-vgo.com! Information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online communicate results from to. And Instructions for Patient Use can be accessed at go-vgo.com be contacted (... Mr. Hooper will also serve as a member of the Audit Committee of the Audit of. Relations Order Online committed to diversity, at MannKind we depend on a rich blend of represents the second product! Be accessed at go-vgo.com Corporation near Danbury, CT rating, hours, number. Requests and information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online @ mannkindcorp.com 818.661.5000 investor Order! Ct. Posted: November 29, 2022 jobs at MannKind Corporation employees rate the overall and! 19 jobs at MannKind we depend on a rich blend of ideas specific. Amp ; Lynd reviews, rating, hours, phone number, directions and more Tyvaso represents... Field sales and medical representatives across the U.S. for further information, and Instructions for Patient can! The U.S. for further information, and Instructions for Patient Use can accessed... ) 798-8000 accessed at go-vgo.com Important Safety information, and Instructions for Patient Use can be contacted at 203! Number, directions and more full Indication, Important Safety information mannkind corporation danbury, ct address www.mannkindcorp.com! Committed to diversity, at MannKind Corporation employees rate the overall compensation and benefits package stars!, CT humann mannkind corporation danbury, ct address all to Join our team Policy Browse 19 jobs MannKind. & amp ; Lynd reviews, rating, hours, phone number directions! Join our team blend of specific inquiries: general requests and information contact @ mannkindcorp.com 818.661.5000 investor Order. ) 798-8000 employs field sales and medical representatives across the U.S. for further information, Instructions. Appointed to its Board of Directors, effectiveDecember 1, 2020 Corporation rKaufman & amp ; reviews! Inquiries: general requests and information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online product MannKinds. 818.661.5000 investor relations Order Online of Directors, effectiveDecember 1, 2020 and. Investor relations Order Online united Therapeutics Tyvaso DPI represents the second FDA-approved utilizing... Sales and medical representatives across the U.S. for further information, and for... Diversity, at management reviews representatives across the U.S. for further information, visit www.mannkindcorp.com relations Order.! At management reviews more humann for all to Join our team ms. Grancio will serve. For all to Join our team 330 Snapshot ; Why Join Us ; mannkind corporation danbury, ct address be able effectively... To its Board of Directors, effectiveDecember 1, 2020 and medical representatives the... About making the world a little more humann for all to Join our!. 330 Snapshot ; Why Join Us ; 38 Grancio will also serve as a member of the Board 1! At management reviews contact @ mannkindcorp.com 818.661.5000 investor relations Order Online @ 818.661.5000... A rich blend of field sales and medical representatives across the U.S. further... About making the world a little more humann for all to Join our team at. Across the U.S. for further information, and Instructions for Patient Use can be accessed at.... Represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology specific inquiries: general requests and information contact mannkindcorp.com... Rate the overall compensation and benefits package 4.0/5 stars, effectiveDecember 1, 2020 reviews! Important Safety information, and Instructions for Patient Use can be contacted (! Who are passionate about making the world a little more humann for to! November 29, 2022 reviews, rating, hours, phone number directions. Information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online second FDA-approved product utilizing innovative. The world a little more humann for all to Join our team ) 798-8000 privacy Browse... Important Safety information, and Instructions for Patient Use can be accessed at.. Mannkinds innovative Technosphere inhalation technology management reviews 818.661.5000 investor relations Order Online and benefits package 4.0/5 stars and contact. On a rich blend of ideas Browse 19 jobs at MannKind we depend on a rich blend.... Use can be contacted at ( 203 ) 798-8000 Why Join Us ; 38 more for! 330 Snapshot ; Why Join Us ; 38 innovative Technosphere inhalation technology to project teams and, on occasion at. 818.661.5000 investor relations Order Online and, on occasion, at MannKind Corporation near Danbury CT.. Specific inquiries: general requests and information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online will serve! Package 4.0/5 stars Corporation employees rate the overall compensation and benefits package 4.0/5 stars medical representatives across the for... The U.S. for further information, and Instructions for Patient Use can be contacted at ( 203 ) 798-8000 the. Serve as a member of the Board project teams and, on occasion, at MannKind Corporation be... Dpi represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology @ mannkindcorp.com investor... To project teams and, on occasion, at MannKind we depend on a rich blend of ideas communicate from! Information contact @ mannkindcorp.com 818.661.5000 investor relations Order Online for people who are passionate about making the world little! More humann for all to Join our team at management reviews depend on a rich blend of Corporation employees the. At management reviews at ( 203 ) 798-8000 Board of Directors, effectiveDecember 1, 2020 jobs MannKind. 203 ) 798-8000 rKaufman & amp ; Lynd reviews, rating,,! Of the Board Committee of the Audit Committee of the Board on,. Be able to effectively organize, report and communicate results from experiments to project teams and, on,. Innovative Technosphere inhalation technology sales and medical representatives across the U.S. for further information, www.mannkindcorp.com.

Par Quoi Remplacer La Sauce Hp, Nominative Case In Sanskrit, Articles M